分享

前门驱狼,后门进虎!新冠阴霾未散,它又要来了,怎么办?

 Dr老爸的育儿经 2023-06-08 发布于四川

这是一个多事之秋。

新冠的阴霾还未消散,流感又在一旁虎视眈眈!


01

什么是流感?

流感,全称“流行性感冒”,虽然名字里面带有“感冒”两个字,但是,与普通感冒大相径庭。

1、首先,症状重:持续发热,全身疼痛,咳嗽,儿童还常常出现呕吐,腹泻,等等。

2、其次,并发症多,如:肺炎,有国外学者连续统计了7年的流感住院患儿,发现其中28%存在肺炎。

中耳炎,约10~50%的流感患儿会并发中耳炎。

不仅如此,还有很多严重并发症,如呼吸衰竭脑炎心肌炎,等等。

3、所以,流感可造成儿童及老人死亡率增加,虽然比不上新冠,但也不可忽视;在流感大流行期间,也可造成年轻成人的死亡率增加。

4、我们还必须知道,流感每年都会爆发,只是,程度不同而已。


02

如何预防流感?

免疫接种是预防流感最为有效的方法!

美国CDC免疫实践咨询委员会(ACIP)美国儿科学会(AAP)推荐所有6月龄及以上者都要每年接种流感疫苗。

北半球的流感季一般为10月到次年5月,而接种疫苗后产生具有保护水平的抗体,大约需要2~4周

所以,大家算算看,该打了吗?

有人说,我去年已经打过了,今年是不是可以不用打了?

不是!

流感疫苗的保护效力一般只能维持数月,所以,还得打。


03

几个常见问题

关于流感疫苗,以下是几个常见问题:

1、孩子什么年龄可以注射流感疫苗?

所有大于等于6个月(180天),没有禁忌症的人,都可以注射。

2、哪些是禁忌症?

(1)对疫苗中的某种成分过敏者;

(2)急性疾病患者,建议症状消退后再接种;

(3)免疫缺陷等问题,不能接种减毒活疫苗;

(4)某些疾病或特殊情况,具体请咨询免疫接种医生。

3、孕妇能接种吗?

美国CDC免疫实践咨询委员会(ACIP)推荐,对所有阶段的妊娠女性及流感季期间可能妊娠的女性接种流感灭活疫苗,但不能接种减毒活疫苗

4、接种疫苗后,还可能患上流感吗?

有可能。

流感病毒分为很多种不同的毒株,流感疫苗的保护作用,很大程度上取决于疫苗所含病毒株与流感季期间流行的病毒株之间的“相符”或“匹配”程度。

如果相符程度高,估计其预防率约为50%-80%。如果相符程度低,效果下降,但仍可显著降低流感的并发症和死亡率。

5、哪些人是重点人群,应该优先接种?

我国推荐以下人群为流感疫苗优先接种对象:

(1) 6~23月龄的婴幼儿。

(2) 2~5岁儿童。

(3) 60岁及以上老年人。

(4) 特定慢性病患者:心血管疾病(单纯高血压除外)、慢性呼吸系统疾病、肝肾功能不全、血液病、神经系统疾病、神经肌肉功能障碍、代谢性疾病(包括糖尿病)等慢性病患者,患有免疫抑制疾病或免疫功能低下者。

(5) 医务人员。

(6) 6月龄以下婴儿的家庭成员和看护人员。

(7) 孕妇或准备在流感季节怀孕的女性。

6. 流感疫苗要接种几剂?

我国流感疫苗接种指南建议:

6月龄~8岁儿童:首次接种应接种2剂,间隔≥4周(28天);如上个流感季或之前接种过一剂或以上流感疫苗的儿童,接种1剂,之后每年1剂。

≥9岁儿童及成人:每年接种1剂。

部分产品说明书的规定略有不同。

7、接种流感疫苗,有不良反应吗?

(1)最常见的不良反应为注射部位的局部疼痛;

(2)可能会发热,特别是2岁以下儿童常见,发生率约为10~35%,通常于接种疫苗后24小时内出现。

(3)严重不良反应,是比较罕见的。

值得提出的是,有一种疾病,格林巴利综合征,这是一种可能引起瘫痪的疾病,流感疫苗的接种可能增加患此病的风险,但风险很低且存在争议。

04

小结

总之,接种流感疫苗,利大于弊,特别是在新冠疫情这个特殊时期。

因为它们都是呼吸道传染病,症状类似,提前接种流感疫苗,即使出现相应症状,也便于医生进行病情判断,以免贻误。

2020年,我国流感疫苗批签发量预计比2019年翻番,达到5000万剂。不过,这也仅能覆盖我国4%的人口,人群整体接种率仍较低。

相较于美国,其在2018年11月初,流感疫苗覆盖率就达到了约45%。

差距,就是这么大!

疫苗接种,一般是通过社区医院等基层医疗机构预约,如有意向,请尽快预约。


参考文献


[1] Dawood FS, Chaves SS, Pérez A, et al. Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010. J Infect Dis 2014; 209:686.
[2] Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis 2004; 190:1369.
[3] Silvennoinen H, Peltola V, Lehtinen P, et al. Clinical presentation of influenza in unselected children treated as outpatients. Pediatr Infect Dis J 2009; 28:372.
[4] Henderson FW, Collier AM, Sanyal MA, et al. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med 1982; 306:1377.
[5] COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2019-2020. Pediatrics 2019; 144.
[6] Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season. MMWR Recomm Rep 2019; 68:1.
[7] Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep 2018; 67:1.
[8] Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25:2842.
[9] Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513.
[10] Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008; 26 Suppl 4:D17.
[11] Giezeman KM, Nauta J, de Bruijn IA, Palache AM. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity. Vaccine 2009; 27:2414.
[12] Belshe RB, Coelingh K, Ambrose CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149.
[13] Sambhara S, Stephenson I. Moving influenza vaccines forward. Expert Rev Vaccines 2009; 8:375.
[14] DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012; 31:49.
[15] Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36.
[16] Jain VK, Rivera L, Zaman K, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 2013; 369:2481.
[17] Centers for Disease Control and Prevention (CDC). Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 2008; 57:393.
[18] Szilagyi PG, Fairbrother G, Griffin MR, et al. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Arch Pediatr Adolesc Med 2008; 162:943.
[19] Eisenberg KW, Szilagyi PG, Fairbrother G, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics 2008; 122:911.
[20] Rolfes MA, Flannery B, Chung JR, et al. Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. Clin Infect Dis 2019; 69:1845.
[21]  CDC. Frequently Asked Influenza (Flu) Questions: 2020-2021 Season.
https://www./flu/season/faq-flu-season-2020-2021.htm
[22] 中国疾病预防控制中心. 中国流感疫苗预防接种技术指南(2019-2020).
[23] Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685.
[24] American Academy of Pediatrics. Influenza. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.476.
[25] Skowronski DM, Jacobsen K, Daigneault J, et al. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics 2006; 117:1963.
[26] Rosenberg M, Sparks R, McMahon A, et al. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009; 27:4278.
[27] Ohmit SE, Gross J, Victor JC, Monto AS. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. Vaccine 2009; 27:1050.
[28] Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; :CD004879.

    转藏 分享 献花(0

    0条评论

    发表

    请遵守用户 评论公约

    类似文章 更多